BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30422819)

  • 1. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
    Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
    J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
    Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.
    Li C; Mishra AS; Gil S; Wang M; Georgakopoulou A; Papayannopoulou T; Hawkins RD; Lieber A
    Mol Ther; 2019 Dec; 27(12):2195-2212. PubMed ID: 31494053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
    Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
    Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.
    Richter M; Saydaminova K; Yumul R; Krishnan R; Liu J; Nagy EE; Singh M; Izsvák Z; Cattaneo R; Uckert W; Palmer D; Ng P; Haworth KG; Kiem HP; Ehrhardt A; Papayannopoulou T; Lieber A
    Blood; 2016 Nov; 128(18):2206-2217. PubMed ID: 27554082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.
    Li C; Psatha N; Wang H; Singh M; Samal HB; Zhang W; Ehrhardt A; Izsvák Z; Papayannopoulou T; Lieber A
    Mol Ther Methods Clin Dev; 2018 Jun; 9():142-152. PubMed ID: 29766024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of FV vectors with human α- or β-globin gene regulatory elements for the correction of β-thalassemia.
    Morianos I; Siapati EK; Pongas G; Vassilopoulos G
    Gene Ther; 2012 Mar; 19(3):303-11. PubMed ID: 21734726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
    Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
    Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
    Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
    Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
    Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.
    Persons DA; Allay ER; Sabatino DE; Kelly P; Bodine DM; Nienhuis AW
    Blood; 2001 May; 97(10):3275-82. PubMed ID: 11342459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic therapy for beta-thalassemia: from the bench to the bedside.
    Arumugam P; Malik P
    Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice.
    Tan M; Qing K; Zhou S; Yoder MC; Srivastava A
    Mol Ther; 2001 Jun; 3(6):940-6. PubMed ID: 11407908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
    Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
    Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.